Monday, April 29, 2019 11:44:50 PM
From CorMedix Website:
Presentation of Lock It 100 at the National Kidney Foundation in Boston May 10th 10:15am during their Late Breaking Research Presentation schedule.
Presenter looks to be a big deal.
Presenter: About Dr. Anil Agarwal, MD
Anil K Agarwal MD, FACP, FASN, FNKF, FASDIN
Professor of Medicine
Chief, Section of Nephrology at University Hospiital East
Director, Interventional Nephrology
Director of Clinical Scholarship for FAME
The Ohio State University Wexner Medical Center
Late-Breaking Research Presentations: The AWARD Trial and The LOCK-IT-100 Study Results
Friday, May 10, 2019 10:15 AM - 11:15 AM Room 312, Hynes Convention Center
Chair: Joseph Vassalotti, MD, FNKF
General CME/CE
Session Description
LOCK-IT-100: LOCK-IT-100, a multicenter, double-blind, active controlled trial randomized 805 hemodialysis (HD) patients using tunneled dialysis catheters at 70 US sites to compare Neutrolin® (an antimicrobial catheter lock solution containing taurolidine 1.35%, citrate 3.5%, & heparin 1000 U/mL) with heparin (1000 U/ml) for efficacy and safety in reducing catheter-related blood stream infections (CRBSIs) in HD patients. The trial was terminated early for efficacy by the Data Safety Monitoring Board, based on a 72% reduction in the risk of CRBSI by Neutrolin® compared to heparin, with no safety concerns identified. The LOCK-IT-100 trial demonstrated reduced risk of CRBSIs, a major cause of preventable hospitalizations, antibiotic use, healthcare costs, and excess mortality in HD.
Objectives
Discuss the results of LOCK-IT-100, a landmark randomized, controlled trial of an investigational catheter lock solution containing taurolidine, which demonstrated a statistically significant reduction in catheter-related bloodstream infections (CRBSIs) in patients on hemodialysis.
Program Tracks
Physician Program
Advanced Practitioner Program
CME/CE Credits/Contact Hours: 1
Presentations
Exercise and Physical Function in Older Adults with Advanced CKD: The AWARD Randomized Controlled Trial
10:15 AM - 10:40 AM
Speakers: Daniel Weiner, MD, MS, FNKF;Stephen Seliger, MD, MS
LOCK-IT-100: An Investigational Antimicrobial Catheter Lock Solution Shown to Reduce Life Threatening Infections in Hemodialysis Patients
10:40 AM - 11:05 AM
Speaker: Anil Agarwal, MD, FNKF
Question & Answer
11:05 AM - 11:15 AM
Speakers: Stephen Seliger, MD, MS;Anil Agarwal, MD, FNKF
Recent CRMD News
- CorMedix Inc. Announces CMS Grants TDAPA to DefenCath • GlobeNewswire Inc. • 04/19/2024 12:30:00 PM
- CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) • GlobeNewswire Inc. • 04/15/2024 12:30:00 PM
- CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:26:20 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 01/18/2024 09:53:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:11:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:10:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:09:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 01:04:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 01:39:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/14/2023 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 09:00:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:11:33 PM
- CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:35:11 PM
- CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference • GlobeNewswire Inc. • 10/11/2023 12:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2023 09:25:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2023 09:20:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/08/2023 08:21:55 PM
- CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology • GlobeNewswire Inc. • 09/08/2023 12:30:00 PM
- CorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath • GlobeNewswire Inc. • 08/30/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 12:30:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 12:12:04 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM